Juan P. Arab, Saul J. Karpen, Paul A. Dawson, Marco Arrese, Michael Trauner – 30 June 2016 – Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches to prevent disease progression to advanced fibrosis or cirrhosis and cancer.

Miriam Cortes, Hector Vilca‐Melendez, Nigel Heaton – 30 June 2016

Mohamed Rela, Ilankumaran Kaliamoorthy, Mettu Srinivas Reddy – 30 June 2016 – Auxiliary partial orthotopic liver transplantation (APOLT) is a technique of liver transplantation (LT) where a partial liver graft is implanted in an orthotopic position after leaving behind a part of the native liver. APOLT was previously considered technically challenging with results inferior to orthotopic liver transplantation.

Julien Calderaro, Benoît Rousseau, Giuliana Amaddeo, Marion Mercey, Cécile Charpy, Charlotte Costentin, Alain Luciani, Elie‐Serge Zafrani, Alexis Laurent, Daniel Azoulay, Fouad Lafdil, Jean‐Michel Pawlotsky – 30 June 2016 – The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of sorafenib, the current standard of care for advanced disease.

Di Wu, Guoyuan Liu, Yufeng Liu, Hexige Saiyin, Chenji Wang, Zhen Wei, Wenjiao Zen, Danyang Liu, Qi Chen, Zhonghua Zhao, Liping Zou, Haojie Huang, Songmin Jiang, Long Yu – 30 June 2016 – Interplay between cell polarity module Scribble‐Lethal Giant Larvae‐Discs Large 1 (DLG1) and Yes‐associated protein (YAP) appears critical in tumor metastasis. We identified zinc finger protein 191 (ZNF191) as a metastasis suppressor acting through DLG‐YAP crosstalk in hepatocellular carcinoma (HCC).

Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.

Adrian Reuben – 28 June 2016

Jannick Prentoe, Rodrigo Velázquez‐Moctezuma, Steven K.H. Foung, Mansun Law, Jens Bukh – 28 June 2016 – There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of important epitopes by hypervariable region 1 (HVR1) of E2 are believed to be major hindrances to developing universally protective HCV vaccines.

Andrea A. Tooley, Seth Sweetser – 28 June 2016

Dinesh Ganapathy, Jasmohan S. Bajaj – 28 June 2016